ES2129078T3 - Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion. - Google Patents

Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.

Info

Publication number
ES2129078T3
ES2129078T3 ES93902271T ES93902271T ES2129078T3 ES 2129078 T3 ES2129078 T3 ES 2129078T3 ES 93902271 T ES93902271 T ES 93902271T ES 93902271 T ES93902271 T ES 93902271T ES 2129078 T3 ES2129078 T3 ES 2129078T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
beta
compound capable
antibiotics
degrading beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93902271T
Other languages
English (en)
Inventor
Pekka Untamo Heino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remedy Consulting Oy
Original Assignee
Remedy Consulting Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Consulting Oy filed Critical Remedy Consulting Oy
Application granted granted Critical
Publication of ES2129078T3 publication Critical patent/ES2129078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01004—Amidase (3.5.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UN USO SANITARIO, UN METODO SANITARIO Y UNA PREPARACION FARMACEUTICA. LA INVENCION PERMITE QUE LA ACCION DE ANTIBIOTICOS (BETA)-LACTAMA SE DIRIJA Y SUS EFECTOS LATERALES SE REDUZCAN POR LA INACTIVACION DE PARTE DEL ANTIBIOTICO EN UN SECTOR DESEADO DEL TRACTO DIGESTIVO DISTAL DEL ESTOMAGO ADMINISTRANDO, SEPARADAMENTE DESDE O SIMULTANEAMENTE CON EL ANTIBIOTICO, UNA ENZIMA, COMO (BETA)-LACTAMASA, LA CUAL ROMPE LA RESISTENCIA DE DICHO ANTIBIOTICO.
ES93902271T 1992-01-17 1993-01-18 Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion. Expired - Lifetime ES2129078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI920206A FI920206A0 (fi) 1992-01-17 1992-01-17 Medicinsk anvaendning, medicinskt foerfarande och preparat.

Publications (1)

Publication Number Publication Date
ES2129078T3 true ES2129078T3 (es) 1999-06-01

Family

ID=8534042

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93902271T Expired - Lifetime ES2129078T3 (es) 1992-01-17 1993-01-18 Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.

Country Status (9)

Country Link
US (1) US5607671A (es)
EP (1) EP0671942B1 (es)
AT (1) ATE174513T1 (es)
DE (1) DE69322659T2 (es)
DK (1) DK0671942T3 (es)
ES (1) ES2129078T3 (es)
FI (1) FI920206A0 (es)
GR (1) GR3029699T3 (es)
WO (1) WO1993013795A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711128C (en) * 1996-05-09 2002-11-07 Sankyo Company Limited Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
FI109970B (fi) * 2002-02-20 2002-11-15 Remedal Oy Valmiste ja menetelmä painon pudottamiseksi
FR2843301B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
FR2843302B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
WO2006085075A2 (en) * 2005-02-09 2006-08-17 Da Volterra Colonic delivery of active agents
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
KR20100020480A (ko) * 2007-05-21 2010-02-22 페노믹스 코포레이션 Ｄｐｐ-ｉｖ 저해제를 위한 안정한 약제학적 제제
ITBO20080297A1 (it) * 2008-05-16 2009-11-17 Archimede R & D S R L Composizione enzimatica per ridurre il rilascio di principi attivi farmaceutici nell'ambiente.
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
ITMI20121715A1 (it) * 2012-10-11 2014-04-12 Bioikos Ambiente S R L Composizioni farmaceutiche con ridotto impatto ambientale
JP6685925B2 (ja) 2014-04-17 2020-04-22 シンセティック バイオロジクス，インコーポレイテッド 治療用として改善された特性を有するβ−ラクタマーゼ
JP6803328B2 (ja) 2014-08-28 2021-01-06 シンセティック バイオロジクス，インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
KR102467968B1 (ko) 2014-10-08 2022-11-16 신세틱 바이오로직스, 인코퍼레이티드 베타-락타마제 제형 및 이의 용도
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
EP3261662B1 (en) 2015-02-23 2021-07-21 Synthetic Biologics Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
AU2016229976B2 (en) 2015-03-06 2021-11-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US10988749B2 (en) 2016-02-23 2021-04-27 Da Volterra Beta-lactamase variants
CA3013166A1 (en) 2016-02-23 2017-08-31 Da Volterra Beta-lactamase variants
JP7223015B2 (ja) 2017-10-25 2023-02-15 ダ・ヴォルテッラ β－ラクタマーゼ変異体
ES3023261T3 (en) * 2019-05-06 2025-05-30 Theriva Biologics Inc Beta-lactamase compositions for treatment of graft versus host disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613624B1 (fr) * 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CS275231B2 (en) * 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle

Also Published As

Publication number Publication date
WO1993013795A1 (en) 1993-07-22
EP0671942B1 (en) 1998-12-16
FI920206A0 (fi) 1992-01-17
EP0671942A1 (en) 1995-09-20
DE69322659D1 (de) 1999-01-28
ATE174513T1 (de) 1999-01-15
US5607671A (en) 1997-03-04
DK0671942T3 (da) 1999-08-23
DE69322659T2 (de) 2000-01-05
GR3029699T3 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
HRP20041084B1 (hr) C-aril glukozid inhibitori sglt2 i postupak
ES2081531T3 (es) Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
ATE169299T1 (de) Antivirale 2-ethyl-1h-imidazo(4,5-c)chinolin-4- amine
AR005009A1 (es) Monohidrato del cdch, procedimiento para su produccion , composiciones antibacteriales que lo contienen, uso del monohidrato del cdch para la manufactura de medicamentos.
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
BRPI0208957B8 (pt) composto, uso de um composto, composição farmacêutica e sal
ES2159591T3 (es) Composicion de liberacion controlada.
IT8723134A0 (it) Procedimento per la fabbricazione di dispositivi integrati cmos con lunghezze di porta ridotte.
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
ES2083668T5 (es) Combinaciones antiviricas que contienen analogos de nucleosido.
ES2037385T3 (es) Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
BR9810495A (pt) Composição farmacêutica
HUP9900492A2 (hu) 3,6-Ketál és enol-éter makrolid antibiotikumok és ezeket tartalmazó gyógyszerkészítmények
ES2173391T3 (es) Derivados de 2-aminobenzazepina y su uso para el tratamiento de la inmunodepresion.
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
PA8515601A1 (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
AR022570A1 (es) COMPOSICIONES EXTRUIDAS LIVIANAS QUE CONTIENEN UN PORTADOR CERÁMICO LIVIANO EXTRUIBLE, MÉTODOS DE USO DE LAS MISMAS Y PROCESOS PARA SU PREPARACIoN.
ES2145114T3 (es) Combinacion de atovacuona con proguanil para el tratamiento de infecciones protozoarias.
ES2125309T3 (es) Derivados de tiomarinol y procedimientos para su preparacion.
ES2159676T3 (es) Derivados de triazol con actividad antimicotica e intermediarios.
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671942

Country of ref document: ES